1.Alternative Name:4-1BB,TNFRSF9;4-1BB ligand receptor; 41BB; 4-1BB; CD137 antigen; CD137; CD137MGC2172; CDw137; FLJ43501; ILA; ILAhomolog of mouse 4-1BB; induced by lymphocyte activation (ILA); interleukin-activated receptor, homolog of mouse Ly63; receptor protein 4-1BB; T cell antigen ILA; T-cell antigen 4-1BB homolog; T-cell antigen ILA; TNFRSF9; tumor necrosis factor receptor superfamily member 9; tumor necrosis factor receptor superfamily, member 9
2.Target:CD137
3.Source:Human CD137 was expressed from HEK293 with poly His at the C-terminal
4.Sequence:Glu19-Ser184
5.Protein structure:Q07011His
6.Molecular Characterization:The protein has a calculated MW of 19kDa.The reducing (R) heterodimer protein migrates as 30-50 kDa due to glycosylation
7.Purity:SDS-PAGE>90%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .


11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

12.SPR

Recombinant Human CD137L[TNFSF9]/mFC Protein（Cat.No.R7755）captured on Protein A chip , can bind Recombinant Human CD137/ His Protein（Cat.No.B21514701） with a KD constant of 1.14E-08 M, determined in a SPR assay .

13.ELISA

When Recombinant Human CD137/ His Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CD137(Utomilumab) that produces 50% of the optimal binding response is approximately 4 ng/ml.

14.ELISA

When Recombinant Human CD137/ His Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Recombinant Human CD137L[TNFSF9]/mFC Protein that produces 50% of the optimal binding response is approximately 20 ng/ml.